Pentostatin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Cytostatic, antimetabolite, purine antagonist.

Pharmacodynamics (Effect)This section has been translated automatically.

Irreversible catalysis of the deamination from adenosine to inosine and from deoxyadenosine to deoxyinosine. Disruption of DNA synthesis, induction of apoptosis.

IndicationThis section has been translated automatically.

Hair cell leukemia, B-cell type CLL, prolymphocytic leukemia, cutaneous T-cell lymphomas.

Dosage and method of useThis section has been translated automatically.

4 mg/m2 KO/day i.v. as a bolus every 2 weeks

Notice!

Before administration intravenous fluid substitution of 500-1000 ml!

Undesirable effectsThis section has been translated automatically.

Myelosuppression, nausea, allergic reactions, fever, fatigue, headaches, liver and kidney dysfunction.

InteractionsThis section has been translated automatically.

Myelotoxic substances.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, children < 16 years.

PreparationsThis section has been translated automatically.

Nipent

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer